135 related articles for article (PubMed ID: 19726758)
1. Transmembrane domain-mediated orientation of receptor monomers in active VEGFR-2 dimers.
Dosch DD; Ballmer-Hofer K
FASEB J; 2010 Jan; 24(1):32-8. PubMed ID: 19726758
[TBL] [Abstract][Full Text] [Related]
2. Role of the growth hormone (GH) receptor transmembrane domain in receptor predimerization and GH-induced activation.
Yang N; Wang X; Jiang J; Frank SJ
Mol Endocrinol; 2007 Jul; 21(7):1642-55. PubMed ID: 17456794
[TBL] [Abstract][Full Text] [Related]
3. Orf virus VEGF-E NZ2 promotes paracellular NRP-1/VEGFR-2 coreceptor assembly via the peptide RPPR.
Cébe-Suarez S; Grünewald FS; Jaussi R; Li X; Claesson-Welsh L; Spillmann D; Mercer AA; Prota AE; Ballmer-Hofer K
FASEB J; 2008 Aug; 22(8):3078-86. PubMed ID: 18467594
[TBL] [Abstract][Full Text] [Related]
4. A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E, mediates angiogenesis via signalling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases.
Meyer M; Clauss M; Lepple-Wienhues A; Waltenberger J; Augustin HG; Ziche M; Lanz C; Büttner M; Rziha HJ; Dehio C
EMBO J; 1999 Jan; 18(2):363-74. PubMed ID: 9889193
[TBL] [Abstract][Full Text] [Related]
5. Structural and functional characterization of alternative transmembrane domain conformations in VEGF receptor 2 activation.
Manni S; Mineev KS; Usmanova D; Lyukmanova EN; Shulepko MA; Kirpichnikov MP; Winter J; Matkovic M; Deupi X; Arseniev AS; Ballmer-Hofer K
Structure; 2014 Aug; 22(8):1077-1089. PubMed ID: 24980797
[TBL] [Abstract][Full Text] [Related]
6. Structure of a VEGF-VEGF receptor complex determined by electron microscopy.
Ruch C; Skiniotis G; Steinmetz MO; Walz T; Ballmer-Hofer K
Nat Struct Mol Biol; 2007 Mar; 14(3):249-50. PubMed ID: 17293873
[TBL] [Abstract][Full Text] [Related]
7. Structure and function of VEGF receptors.
Stuttfeld E; Ballmer-Hofer K
IUBMB Life; 2009 Sep; 61(9):915-22. PubMed ID: 19658168
[TBL] [Abstract][Full Text] [Related]
8. Chimeric VEGFRs are activated by a small-molecule dimerizer and mediate downstream signalling cascades in endothelial cells.
Knight EL; Warner AJ; Maxwell A; Prigent SA
Oncogene; 2000 Nov; 19(47):5398-405. PubMed ID: 11103941
[TBL] [Abstract][Full Text] [Related]
9. Cysteine at position 217 in the intracellular loop 1 plays a critical role in human PTH receptor type 1 membrane translocation and function.
Thomas BE; Wittelsberger A; Woznica I; Hsieh MY; Monaghan P; Lee BK; Rosenblatt M
J Bone Miner Res; 2007 Apr; 22(4):609-16. PubMed ID: 17227205
[TBL] [Abstract][Full Text] [Related]
10. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.
Joukov V; Pajusola K; Kaipainen A; Chilov D; Lahtinen I; Kukk E; Saksela O; Kalkkinen N; Alitalo K
EMBO J; 1996 Jan; 15(2):290-98. PubMed ID: 8617204
[TBL] [Abstract][Full Text] [Related]
11. Identification of VEGF receptor-2 tyrosine phosphorylation sites involved in VEGF-mediated endothelial platelet-activating factor synthesis.
Rechka A; Neagoe PE; Gratton JP; Sirois MG
Can J Physiol Pharmacol; 2010 Oct; 88(10):968-76. PubMed ID: 20962896
[TBL] [Abstract][Full Text] [Related]
12. Sap-1/PTPRH activity is regulated by reversible dimerization.
Wälchli S; Espanel X; Hooft van Huijsduijnen R
Biochem Biophys Res Commun; 2005 Jun; 331(2):497-502. PubMed ID: 15850787
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin-like domain 4-mediated ligand-independent dimerization triggers VEGFR-2 activation in HUVECs and VEGFR2-positive breast cancer cells.
Zhang S; Gao X; Fu W; Li S; Yue L
Breast Cancer Res Treat; 2017 Jun; 163(3):423-434. PubMed ID: 28303365
[TBL] [Abstract][Full Text] [Related]
14. Role of aspartate 351 in transactivation and active conformation of estrogen receptor alpha.
Kim JH; Lee MH; Kim BJ; Kim JH; Han SJ; Kim HY; Stallcup MR
J Mol Endocrinol; 2005 Dec; 35(3):449-64. PubMed ID: 16326832
[TBL] [Abstract][Full Text] [Related]
15. Structural analysis of vascular endothelial growth factor receptor-2/ligand complexes by small-angle X-ray solution scattering.
Kisko K; Brozzo MS; Missimer J; Schleier T; Menzel A; Leppänen VM; Alitalo K; Walzthoeni T; Aebersold R; Ballmer-Hofer K
FASEB J; 2011 Sep; 25(9):2980-6. PubMed ID: 21613573
[TBL] [Abstract][Full Text] [Related]
16. Role of extracellular domain dimerization in agonist-induced activation of natriuretic peptide receptor A.
Parat M; McNicoll N; Wilkes B; Fournier A; De Léan A
Mol Pharmacol; 2008 Feb; 73(2):431-40. PubMed ID: 17965196
[TBL] [Abstract][Full Text] [Related]
17. Structural determinants of growth factor binding and specificity by VEGF receptor 2.
Leppänen VM; Prota AE; Jeltsch M; Anisimov A; Kalkkinen N; Strandin T; Lankinen H; Goldman A; Ballmer-Hofer K; Alitalo K
Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2425-30. PubMed ID: 20145116
[TBL] [Abstract][Full Text] [Related]
18. Model for growth hormone receptor activation based on subunit rotation within a receptor dimer.
Brown RJ; Adams JJ; Pelekanos RA; Wan Y; McKinstry WJ; Palethorpe K; Seeber RM; Monks TA; Eidne KA; Parker MW; Waters MJ
Nat Struct Mol Biol; 2005 Sep; 12(9):814-21. PubMed ID: 16116438
[TBL] [Abstract][Full Text] [Related]
19. Functional and structural characterization of the kinase insert and the carboxy terminal domain in VEGF receptor 2 activation.
Manni S; Kisko K; Schleier T; Missimer J; Ballmer-Hofer K
FASEB J; 2014 Nov; 28(11):4914-23. PubMed ID: 25114179
[TBL] [Abstract][Full Text] [Related]
20. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation.
Burke CL; Lemmon MA; Coren BA; Engelman DM; Stern DF
Oncogene; 1997 Feb; 14(6):687-96. PubMed ID: 9038376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
